CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 8 enrolled
Drug / intervention
imiquimod +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00504023
NCT00504023N/ACompleted

A Pilot Study of Topical Imiquimod Therapy for the Treatment of Recurrent Extramammary Paget's Disease

Memorial Sloan Kettering Cancer Center·interventional·Posted Jul 19, 2007·Updated Jun 6, 2018

In Brief

A clinical study evaluating imiquimod, biopsy, and 1 other intervention for Vulvar Cancer. Completed, enrolled 8 participants across 2 sites.

Detailed Summary

RATIONALE: Biological therapies, such as imiquimod, may stimulate the immune system in different ways and stop tumor cells from growing. Applying topical imiquimod to the vulva may be an effective treatment for recurrent Paget's disease. PURPOSE: This clinical trial is studying how well topical imiquimod works in treating patients with recurrent Paget's disease of the vulva.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsVulvar Cancer
CountriesUnited States

Timeline

N/ACompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJul 19, 2007
Enrollment StartApr 1, 2007
Primary CompletionJan 1, 2018
TodayJul 2, 2026
Enrollment to primary: 10.8 yearsPosted 19.0 years ago

Interventions

imiquimoddrug

The patient will be seen in clinic every six weeks during treatment for examination. Imiquimod cream is to be applied 3 times per week for 12 weeks.

biopsyprocedure

Punch biopsy and photography will be performed at the baseline and 12 week time points.

therapeutic conventional surgeryprocedure

If the lesion is still present after 12 weeks of therapy, the treating physician will recommend excision of the lesion four weeks after completion of therapy (week 16).